Contents 2 min read

Claim and source comparison

Comparison limited to two sleep meta-analysis abstracts, a six-person constituent pharmacokinetic abstract and NCCIH safety information; not a full clinical review.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Systematic review / meta-analysis

Bent et al. (2006) reviewed 16 studies with 1093 participants. Six studies assessing sleep quality as improved/not improved produced a relative risk of 1.8 (95% CI 1.2–2.9).

Products, doses and methods differed, with publication bias. A subjective binary outcome does not establish objective sleep improvement or efficacy of every valerian product.

Source 1 · Abstract read

Systematic review / meta-analysis

Fernández-San-Martín et al. (2010) found no significant difference in quantitative sleep latency or sleep-quality measures across 18 randomized trials. The binary subjective sleep-quality outcome favored valerian.

Studies were heterogeneous. A positive result on one measurement format does not resolve uncertainty in other measures or establish treatment of chronic insomnia.

Source 3 · Abstract read

Human pharmacokinetic study

Anderson et al. (2005) gave six healthy people a single 600 mg dose of valerian. Mean elimination half-life of serum valerenic acid was 1.1 ± 0.6 hours.

This measures one constituent, not whole-extract half-life, duration of sleep effects or hours before bedtime. A small pharmacokinetic study does not establish efficacy, a safe dose or a personal schedule.

Source 6 · Abstract read

Official safety summary

NCCIH advises against taking valerian with alcohol or sedatives. Mental dullness, headache, stomach upset and vivid dreams have been reported; long-term safety is unknown. Withdrawal symptoms have been reported after abrupt cessation following chronic use.

Official information provides neither adverse-event rates for every product nor safe combination thresholds. Pregnancy and breastfeeding data are limited; short-term tolerability does not establish long-term safety.

Source 5 · Official summary read

Our evidence and source methodology

valerian: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Valerian?

Valerian is an herb studied for sleep problems; human findings are inconsistent. It may cause mental dullness and should not be combined with alcohol or sedatives.

Clinical Evidence

Bent et al. (2006) reviewed 16 studies with 1093 participants. Six studies assessing sleep quality as improved/not improved produced a relative risk of 1.8 (95% CI 1.2–2.9).

Products, doses and methods differed, with publication bias. A subjective binary outcome does not establish objective sleep improvement or efficacy of every valerian product.

Fernández-San-Martín et al. (2010) found no significant difference in quantitative sleep latency or sleep-quality measures across 18 randomized trials. The binary subjective sleep-quality outcome favored valerian.

Studies were heterogeneous. A positive result on one measurement format does not resolve uncertainty in other measures or establish treatment of chronic insomnia.

combinations

The names below are research topics, not combination recommendations. NCCIH advises against taking valerian with alcohol or sedatives. Potentiated sedation does not establish benefit or safety; this list also provides no personal clearance to combine it with melatonin.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Anderson et al. (2005) gave six healthy people a single 600 mg dose of valerian. Mean elimination half-life of serum valerenic acid was 1.1 ± 0.6 hours.

This measures one constituent, not whole-extract half-life, duration of sleep effects or hours before bedtime. A small pharmacokinetic study does not establish efficacy, a safe dose or a personal schedule.

Safety and Side Effects

NCCIH advises against taking valerian with alcohol or sedatives. Mental dullness, headache, stomach upset and vivid dreams have been reported; long-term safety is unknown. Withdrawal symptoms have been reported after abrupt cessation following chronic use.

Official information provides neither adverse-event rates for every product nor safe combination thresholds. Pregnancy and breastfeeding data are limited; short-term tolerability does not establish long-term safety.

Sources

  1. Bent S, et al. (2006). Valerian for sleep: a systematic review and meta-analysis. American Journal of Medicine, 119(12), 1005–1012. PubMed · PMID 17145239
  2. Trauner G, et al. (2008). Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid. Planta Medica, 74(1), 19–24. PubMed · PMID 18095218
  3. Fernández-San-Martín MI, et al. (2010). Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Medicine, 11(6), 505–511. PubMed · PMID 20347389
  4. Koetter U, et al. (2007). A randomized, double blind, placebo-controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder. Phytotherapy Research, 21(9), 847–851. PubMed · PMID 17486686
  5. NIH NCCIH. Valerian: Usefulness and Safety. https://www.nccih.nih.gov/health/valerian NIH NCCIH
  6. Anderson GD, et al. (2005). Pharmacokinetics of valerenic acid after administration of valerian in healthy subjects. Phytotherapy Research, 19(9), 801–803. PubMed · PMID 16220575

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions